Aarti Pharmalabs Limited has informed the Exchange that Board of Directors at its meeting held on May 10, 2025, recommended Final Dividend of 2.50 per equity share.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Aarti Pharmalabs met on May 10, 2025 and approved audited financial results for Q4 and FY ended March 31, 2025, both standalone and consolidated, along with a recommendation for a final dividend of Rs. 2.50 (50%) per equity share of face value Rs. 5, subject to shareholder approval at the upcoming AGM. On a standalone basis, FY25 revenue from operations rose about 18% YoY to Rs. 1,771.4 crore and net profit grew roughly 28% to Rs. 257.3 crore, taking basic EPS to Rs. 28.39. On a consolidated basis, FY25 revenue grew about 14% to Rs. 2,115 crore and net profit rose around 26% to Rs. 272.4 crore, with EPS of Rs. 30.06. Statutory auditors Gokhale & Sathe issued an unqualified opinion, and the Board also appointed Smt. Ketki D. Visariya as Cost Auditor and Manish Modi & Associates as Internal Auditor for FY 2025-26.
Strong double-digit revenue and profit growth, combined with a 50% dividend payout, signals healthy financial health and rewards shareholders; this is likely to be viewed positively by investors and could support the stock near-term. Dividend amount remains modest in absolute terms, so yield impact depends on the prevailing share price.